Skip to main content
Explore URMC

menu

Chemotherapy study for acute myeloid leukemia (AML)

Research Question:
What is the response to chemotherapy with the drug decitabine combined with the drug rapamycin in the treatment of relapsed or refractory acute myeloid leukemia?

Basic Study Information

Purpose:
To evaluate the response to chemotherapy with the drug decitabine combined with rapamycin in the treatment of relapsed or refractory acute myeloid leukemia in patients of all ages, and in the treatment of newly diagnosed leukemia in those who are older than 65 when diagnosed.

Location: University of Rochester Medical Center
Study Reference #: ULEU13049

Lead Researcher (Principal Investigator)

Lead Researcher: Jane Liesveld, MD

Study Contact Information

Study Coordinator: Brandon DeLorme
Phone: (585) 275-5295
Email: Brandon_Delorme@URMC.Rochester.edu

Additional Study Details

Contact This Study

This field is required
This field is required
You must agree to be contacted to continue.

Return to Search